May 1, 2020 / 9:02 PM / a month ago

BRIEF-Genmab Announces U.S. FDA Approval Of Subcutaneous Formulation Of Daratumumab, Darzalex Faspro For The Treatment Of Patients With Multiple Myeloma

May 1 (Reuters) - Genmab A/S:

* GENMAB ANNOUNCES U.S. FDA APPROVAL OF SUBCUTANEOUS FORMULATION OF DARATUMUMAB, DARZALEX FASPRO™ (DARATUMUMAB AND HYALURONIDASE-FIHJ), FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

* GENMAB A/S - SUBCUTANEOUS FORMULATION OF DARATUMUMAB, DARZALEX FASPRO™, APPROVED BY U.S. FDA FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below